Pricing Log in Create free account

INmune Bio, Inc. (INMB) vs Kalaris Therapeutics Inc. (KLRS)

INmune Bio, Inc. and Kalaris Therapeutics Inc. are both Biotechnology companies. INmune Bio, Inc. and Kalaris Therapeutics Inc. are of similar size ($47.8M and $45.8M). Across the 10 metrics below, INmune Bio, Inc. leads on 5 and Kalaris Therapeutics Inc. on 5.

Valuation

Metric INMB KLRS Biotechnology median
P/E n/m n/m 8.50
P/S 310.73 n/m 9.71
P/B 2.06 0.83 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.55 0.64
EV/Sales 210.43 n/m 9.21
Earnings yield (42.68%) (101.00%) (33.15%)
Free cash flow yield (39.17%) (85.89%) (25.50%)

Profitability

Metric INMB KLRS Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (74.82%) (79.91%) (56.36%)
Return on assets (57.08%) (46.02%) (48.04%)
Return on invested capital (646.94%) 0.00% 0.00%

Growth

Metric INMB KLRS Biotechnology median
Revenue growth (TTM) (51.61%) — 6.02%
EPS growth (last fiscal year) 11.85% 94.50% 30.26%
Revenue growth, 5-year CAGR 35.37% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric INMB KLRS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.04 10.98 4.72
Net debt to EBITDA 0.52 2.54 0.96

Dividend

Metric INMB KLRS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric INMB KLRS Biotechnology median
Market cap 45.80m 47.83m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack